Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Covalent BTK Inhibitor Zanubrutinib in Combination With a CD3-CD20 Bispecific Antibody Odronextamab in Patients With Richter's Transformation

NCT06735664 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06735664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06735664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Covalent BTK Inhibitor Zanubrutinib in Combination With a CD3-CD20 Bispecific Antibody Odronextamab in Patients With Richter's Transformation
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
August 14, 2025
Completion date
December 13, 2027
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent transformed chronic lymphocytic leukemia, refractory transformed chronic lymphocytic leukemia, richter syndrome, transformed chronic lymphocytic leukemia to diffuse large b-cell lymphoma